Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Bombesin-Targeted PET of Prostate Cancer JOURNAL OF NUCLEAR MEDICINE Mansi, R., Minamimoto, R., Macke, H., Iagaru, A. H. 2016; 57: 67S-72S

Abstract

Imaging plays an important role in prostate cancer (PC), including accurate evaluation of the extent of disease, assessment of sites of recurrent disease, and monitoring of response to treatment. Molecular imaging techniques are among the novel developments related to the imaging of PC, and various SPECT and PET radiopharmaceuticals are now available in clinical trials or commercially. Here we describe the preclinical and clinical use of gastrin-releasing peptide receptors as targets for the imaging of PC, with a focus on the development of PET tracers for the imaging of gastrin-releasing peptide receptor-positive tumors.

View details for DOI 10.2967/jnumed.115.170977

View details for Web of Science ID 000384962100013

View details for PubMedID 27694175